Karyopharm Therapeutics Inc.
KPTI
$1.62
-$0.08-4.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.43M | 35.07M | 34.08M | 44.04M | 37.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.43M | 35.07M | 34.08M | 44.04M | 37.93M |
| Cost of Revenue | 30.04M | 35.14M | 29.15M | 32.66M | 33.84M |
| Gross Profit | 3.39M | -76.00K | 4.93M | 11.39M | 4.09M |
| SG&A Expenses | 25.92M | 26.68M | 22.77M | 26.61M | 28.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.96M | 61.83M | 51.92M | 59.26M | 62.32M |
| Operating Income | -22.53M | -26.76M | -17.84M | -15.22M | -24.39M |
| Income Before Tax | -67.02M | -22.39M | -102.27M | -33.09M | -37.21M |
| Income Tax Expenses | -- | 1.00K | -67.00K | 34.00K | 40.00K |
| Earnings from Continuing Operations | -67.02M | -22.39M | -102.20M | -33.13M | -37.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.02M | -22.39M | -102.20M | -33.13M | -37.25M |
| EBIT | -22.53M | -26.76M | -17.84M | -15.22M | -24.39M |
| EBITDA | -22.52M | -26.75M | -17.83M | -15.10M | -24.31M |
| EPS Basic | -2.32 | -1.02 | -5.71 | -3.82 | -4.32 |
| Normalized Basic EPS | -1.45 | -0.64 | -1.39 | -2.39 | -2.70 |
| EPS Diluted | -2.32 | -1.24 | -5.71 | -3.82 | -4.32 |
| Normalized Diluted EPS | -1.45 | -0.57 | -1.39 | -2.39 | -2.70 |
| Average Basic Shares Outstanding | 28.94M | 22.01M | 17.90M | 8.67M | 8.62M |
| Average Diluted Shares Outstanding | 28.94M | 24.72M | 17.90M | 8.67M | 8.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |